Hot Investor Mandate 4: Corporate VC Focuses on Preclinical Oncology Therapeutics

13 Oct

A $50 million strategic corporate venture capital fund formed by a pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The fund is currently seeking opportunities in the U.S., Europe and Japan.

The firm considers all modalities of oncology therapeutics with a special interest in biologics. The firm focuses on programs from drug discovery to preclinical development. The firm is looking for assets that have a strategic angle to its parent company’s pipeline.

The firm is looking for teams with strong sector expertise. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: